Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DBV Technologies S.A. (DBVT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret key information. DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy (EPIT) patches for food allergies and other immunologic conditions, and its filings offer detailed insight into this development activity.
Through Forms 8-K, DBV Technologies reports material events such as clinical milestones, financial results, equity offerings, and changes in corporate governance. Examples include announcements of positive topline results from the Phase 3 VITESSE trial of the Viaskin Peanut patch in peanut-allergic children aged 4 to 7 years, quarterly financial results, establishment of an at-the-market ADS offering program, and appointments or resignations of directors and senior leaders.
On this page, users can review filings related to results of operations and financial condition, other events, and board and executive changes, as disclosed under specific SEC items. For a Nasdaq-listed biopharmaceutical company like DBV Technologies, these documents help explain the status of its clinical programs, capital-raising activities, and governance structure.
Stock Titan enhances these filings with AI-generated summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each report. Real-time updates from the EDGAR system ensure that new DBV Technologies filings, including future 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, appear promptly as they are published. Users can also monitor disclosures that may relate to executive compensation, equity issuance, or other regulatory matters connected to the company’s Viaskin-based food allergy programs.
DBV Technologies announced a significant milestone in its clinical research program with the first subject screening in the COMFORT Toddlers Supplemental Safety Study, focusing on peanut-allergic children aged 1-3 years old. This development marks an important step in the company's research into peanut allergy treatments.
The company, which trades on Nasdaq under symbol DBVT through American Depositary Shares (each representing five ordinary shares), filed this 8-K to report the initiation of this clinical study. The announcement was made via press release on June 25, 2025.
Key filing details:
- The study specifically targets toddlers between 1-3 years old with peanut allergies
- The filing includes two exhibits: the press release (99.1) and Cover Page Interactive Data File
- The document was signed by CFO Virginie Boucinha
DBV Technologies has filed a Form S-8 registration statement to register securities related to its 2025 Stock Option Plan and 2025 Free Share Plan. The company, headquartered in Châtillon, France, is classified as a non-accelerated filer and smaller reporting company.
Key aspects of the filing include:
- Registration incorporates previous S-8 filings from October 2014, November 2023, and July 2024
- Includes the company's Annual Report for FY2024 and Q1 2025 Quarterly Report
- Maintains liability insurance for directors and officers with contractual indemnification provisions
- French law prohibits limiting director liability but allows insurance against civil liabilities
The registration is signed by CEO Daniel Tassé and includes authorization from the full board of directors. Michele Robertson serves as the authorized U.S. representative in her capacity as Chief Legal Officer. The filing demonstrates DBV Technologies' commitment to employee equity compensation while maintaining compliance with both U.S. and French regulatory requirements.